Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70207 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, 2025. Written by Chloe Landy and 5 co-authors. Institution: Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia. Major MEDLINE topics: Inflammation, Pulmonary Arterial Hypertension, Sex Characteristics, Hypertension, Pulmonary. Cited 4 times so far (Crossref); 201 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Heart Foundation of Australia, National Health and Medical Research Council, British Heart Foundation.
Abstract (original language)
Pulmonary arterial hypertension (PAH) is a progressive and life‐threatening disease with limited treatment options. Sex differences are apparent in PAH, specifically in the pathophysiology, prognoses and pharmacological responses of patients. Inflammation and its resolution, which often differ between sexes, are dysregulated in chronic inflammatory conditions such as PAH. Inflammation is yet to be directly targeted by available PAH therapies despite its association with poor patient outcomes. Emerging research highlights the resolution of inflammation, an active process that restores tissue homeostasis, as a therapeutic avenue for treating chronic inflammatory diseases. This review encompasses the key pro‐resolving ligands and G protein‐coupled receptors involved in the active resolution of inflammation. We explore their dysregulation in PAH and evaluate their therapeutic potential, with a focus on how sex‐specific immune responses may influence both preclinical findings and clinical outcomes. Signalling pathways involved in the resolution of inflammation present many therapeutically relevant targets for the development of novel PAH therapies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
- Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Africa-Europe CoRE in Non-Communicable Diseases and Multimorbidity, African Research Universities Alliance (ARUA) and The Guild of European Research-intensive Universities, Glasgow, UK.
- Immunology Translational Research Programme, Department of Pharmacology, Yong Loo Lin School of Medicine, Singapore.
ORCID profiles: Miles J De Blasio, Owen L Woodman, Pasquale Maffia, Hong Yong Peh, Cheng Xue Qin
Funding
- National Heart Foundation of Australia
- National Health and Medical Research Council
- British Heart Foundation
Cite
APA
Landy, C., De Blasio, M. J., Woodman, O. L., Maffia, P., Peh, H. Y., & Qin, C. X. (2025). Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review. British Journal of Pharmacology. https://doi.org/10.1111/bph.70207
Vancouver
Landy C, De Blasio MJ, Woodman OL, Maffia P, Peh HY, Qin CX. Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review. British Journal of Pharmacology. 2025. doi:10.1111/bph.70207
BibTeX
@article{Landy2025,
author = {Landy, Chloe and De Blasio, Miles J and Woodman, Owen L and Maffia, Pasquale and Peh, Hong Yong and Qin, Cheng Xue},
title = {Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70207}
}
EUVIMED